• Bloom Health Partners (BLMH) has received DTC eligibility
  • Its shares will continue to trade on the OTCQB Market under the ticker BLMHF
  • DTC eligibility allows Bloom’s existing U.S investors to benefit from electronic clearing and settlement of its shares within the United States
  • Bloom Health Partners Inc. is a global platform for healthcare security, diagnostic testing and occupational health-tech
  • Bloom Health Partners Inc. (BLMH) is flat on the day, trading at C$0.32 at 2:18 pm EST

Common shares of Bloom Health Partners (BLMH) are now eligible for electronic clearing and settlement through the Depository Trust Company.

Its shares will continue to trade in the USA, under the ticker BLMHF on the OTCQB Market.

DTC eligibility reduces costs and accelerates the settlement process for investors and brokers allowing its common shares to be traded over a wider selection of brokerage firms.

“This is an important step in making Bloom’s shares accessible to the widest audience possible, as DTC eligibility allows Bloom’s existing U.S investors to benefit from electronic clearing and settlement of its shares within the United States,” said Andrew Morton, CEO of Bloom.

Bloom Health Partners Inc. is a global platform for healthcare security, diagnostic testing and occupational health tech.

Its mission is to ensure that “unstoppable is possible” for businesses and their employees through innovative, customized healthcare models.

Bloom offers a system for businesses and organizations that helps engage employees and creates strategies to manage health and safety.

Bloom Health Partners Inc. (BLMH) is flat on the day, trading at C$0.32 at 2:18 pm EST.

More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.